Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ART022
MIFTS: 70

Arthritis

Categories: Bone diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Arthritis

About this section

MalaCards integrated aliases for Arthritis:

Name: Arthritis 12 74 29 54 6 42 3 43 15 37 17 71
Inflammatory Joint Disease 54 71
Inflammatory Disorder of Joint 12

Classifications:

MalaCards categories:
Anatomical: Bone diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:848
MeSH 43 D001168
NCIt 49 C2883
SNOMED-CT 67 3723001
UMLS 71 C0003864 C0683381
Sources

Summaries for Arthritis

About this section
MedlinePlus : 42 If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Arthritis, also known as inflammatory joint disease, is related to juvenile rheumatoid arthritis and rheumatoid arthritis, and has symptoms including joint stiffness, arthralgia and back pain. An important gene associated with Arthritis is RELN (Reelin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Betamethasone and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include joint, skin over the joint and bone, and related phenotypes are Increased vaccinia virus (VACV) infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located in joint and/or redness located in skin over the joint.

CDC : 3 Arthritis means inflammation or swelling of one or more joints. It describes more than 100 conditions that affect the joints, tissues around the joint, and other connective tissues. Specific symptoms vary depending on the type of arthritis, but usually include joint pain and stiffness.

Wikipedia : 74 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Sources

Related Diseases for Arthritis

About this section

Diseases in the Arthritis family:

Transient Arthritis

Diseases related to Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2462)
# Related Disease Score Top Affiliating Genes
1 juvenile rheumatoid arthritis 36.1 TNF MMP3 MIF LTA IL6 IL1B
2 rheumatoid arthritis 36.1 TNFSF11 TNF PTPN22 MMP9 MMP3 MMP13
3 psoriatic arthritis 35.9 TNFSF11 TNF PTPN22 NOD2 MMP3 MMP1
4 reactive arthritis 35.6 TNF IL6 IL1B IL17A IL10
5 rheumatoid arthritis, systemic juvenile 35.5 MIF LACC1 IL6
6 systemic onset juvenile idiopathic arthritis 35.3 TNF IL1B
7 psoriatic juvenile idiopathic arthritis 35.3 PSTPIP1 NOD2
8 oligoarticular juvenile idiopathic arthritis 35.1 TNF PTPN22 MIF
9 spondyloarthropathy 1 34.9 TNFSF11 TNF NOD2 MMP3 IL17A
10 osteoarthritis 34.9 TNFSF11 TNF MMP9 MMP3 MMP13 MMP1
11 blau syndrome 34.8 TNF PSTPIP1 NOD2 IL1B IL10
12 psoriasis 34.2 TNF PTPN22 NOD2 LTA IL6 IL1B
13 adult-onset still's disease 34.1 TNF MIF IL6 IL1B
14 systemic lupus erythematosus 34.0 TNF PTPN22 MMP9 MIF LTA IL6
15 lyme disease 34.0 TNF MMP9 IL6 IL1B IL17A
16 behcet syndrome 33.9 TNF PTPN22 PSTPIP1 NOD2 LTA IL6
17 palindromic rheumatism 33.8 TNF PTPN22 IL1B
18 arthropathy 33.8 TNFSF11 TNF MMP3 MMP13 MMP1 LTA
19 rheumatic disease 33.8 TNF MMP3 IL1B IL10
20 fibromyalgia 33.7 TNF IL6 IL1B IL10 CCL2
21 osteoporosis 33.7 TNFSF11 TNF MMP9 MMP3 MIF IL6
22 familial mediterranean fever 33.7 TNF PSTPIP1 NOD2 IL6 IL1B IL17A
23 interstitial lung disease 33.7 TNF MMP9 IL6 IL1B IL1A IL17A
24 connective tissue disease 33.7 TNFSF11 TNF MMP3 MMP13 IL6 IL1B
25 crohn's disease 33.6 TNF PTPN22 NOD2 LACC1 IL6 IL1B
26 carpal tunnel syndrome 33.5 IL6 IL1B CCL2
27 temporal arteritis 33.5 TNF PTPN22 IL6 IL17A CCL2
28 shigellosis 33.5 TNF LTA IL1B IL10
29 dermatitis 33.5 TNF NOD2 IL6 IL1A IL17A IL10
30 sarcoidosis 1 33.5 TNF NOD2 MIF LTA IL1B IL1A
31 bone disease 33.5 TNFSF11 TNF MMP9 MMP13 LTA IL6
32 mixed connective tissue disease 33.5 TNF IL6 IL10
33 bronchiolitis obliterans 33.5 TNF MMP9 IL6 IL17A IL10
34 dermatitis, atopic 33.5 TNF NOD2 MIF LTA IL6 IL1B
35 cartilage disease 33.4 TNF MMP3 MMP13
36 spinal stenosis 33.4 MMP3 MMP13 MMP1
37 neurofibromatosis, type ii 33.4 TNF PSTPIP1 IL6 IL1A
38 osteonecrosis 33.4 TNFSF11 TNF IL10
39 brucellosis 33.4 TNF IL6 IL17A IL10
40 scleritis 33.3 TNF MMP9 CCL2
41 rosacea 33.3 TNF MMP9 MMP3 IL6
42 tropical spastic paraparesis 33.3 MMP9 IL6 IL17A IL10
43 autoimmune disease 33.3 TNF PTPN22 MMP9 MIF LTA IL6
44 rheumatoid nodulosis 33.3 MMP9 MMP3
45 cinca syndrome 33.3 PSTPIP1 NOD2 IL6 IL1B
46 common variable immunodeficiency 33.1 TNF NOD2 IL6 IL10
47 spondylitis 33.0 TNFSF11 TNF NOD2 LTA IL6 IL17A
48 scoliosis 33.0 TNFSF11 RELN MMP9 MMP3 MMP13 IL6
49 synovitis 32.9 TNFSF11 TNF RELN MMP9 MMP3 MMP13
50 uveitis 32.8 TNF NOD2 LTA IL6 IL1A IL17A

Graphical network of the top 20 diseases related to Arthritis:



Diseases related to Arthritis
Sources

Symptoms & Phenotypes for Arthritis

About this section

UMLS symptoms related to Arthritis:


joint stiffness, arthralgia, back pain, sciatica, muscle cramp, metatarsalgia

GenomeRNAi Phenotypes related to Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.96 CCL2 CPT2 IL10 IL17A IL1A IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 IL10 IL17A IL1A IL1B LTA NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 IL10 IL17A IL1A IL1B LTA NOD2

MGI Mouse Phenotypes related to Arthritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CPT2 IL10 IL17A IL1A IL1B IL6
2 hematopoietic system MP:0005397 10.28 IL10 IL17A IL1A IL1B IL6 LACC1
3 immune system MP:0005387 10.28 CCL2 CPT2 IL10 IL17A IL1A IL1B
4 growth/size/body region MP:0005378 10.21 IL10 IL17A IL1B IL6 LTA MMP13
5 cardiovascular system MP:0005385 10.18 CPT2 IL10 IL1A IL1B IL6 LTA
6 digestive/alimentary MP:0005381 10.06 IL10 IL17A IL6 MMP9 NOD2 PTPN22
7 integument MP:0010771 9.96 IL10 IL17A IL1A IL1B IL6 MMP13
8 neoplasm MP:0002006 9.81 IL10 IL1A IL1B IL6 MIF MMP1
9 respiratory system MP:0005388 9.61 CPT2 IL10 IL17A IL6 LTA MMP9
10 skeleton MP:0005390 9.4 CPT2 IL10 IL17A IL1B IL6 LTA
Sources

Drugs & Therapeutics for Arthritis

About this section

Drugs for Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 926)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Azithromycin Approved Phase 4 83905-01-5 55185 447043
4
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
5
Polidocanol Approved Phase 4 9002-92-0
6
Dinoprostone Approved Phase 4 363-24-6 5280360
7 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
9
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
12
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
13 Brodalumab Approved, Investigational Phase 4 1174395-19-7
14
Colchicine Approved Phase 4 64-86-8 6167 2833
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Ticagrelor Approved Phase 4 274693-27-5 9871419
19
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Famotidine Approved Phase 4 76824-35-6 3325
22
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
23
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
24
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
25 Orange Approved Phase 4
26
Aceclofenac Approved, Investigational Phase 4 89796-99-6
27
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Allopurinol Approved Phase 4 315-30-0 2094
30
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
31
Pheniramine Approved Phase 4 86-21-5 4761
32
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
33
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
34
Prilocaine Approved Phase 4 721-50-6 4906
35
Dalteparin Approved Phase 4 9005-49-6
36
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
37
Remifentanil Approved Phase 4 132875-61-7 60815
38
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
39
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
40
alemtuzumab Approved, Investigational Phase 4 216503-57-0
41
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
42
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
43
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
44
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
45
Codeine Approved, Illicit Phase 4 76-57-3 5284371
46
Pancrelipase Approved, Investigational Phase 4 53608-75-6
47
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
48
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
49
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
50 Artichoke Approved Phase 4

Interventional clinical trials:

(show top 50) (show all 4974)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
4 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
5 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
6 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
7 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
8 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
9 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
10 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
11 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
12 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
13 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
14 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
15 A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis Unknown status NCT02780323 Phase 4 CELBESTA®;CELEBREX®;CELEBREX® placebo;CELBESTA® placebo
16 Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity Unknown status NCT02770794 Phase 4 Infliximab
17 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
18 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
19 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
20 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
21 Gait Analysis of Patients Undergoing Total Ankle Arthroplasty, Ankle Arthrodesis, Tibiotalocalcaneal or Pantalar Fusion. Unknown status NCT00921076 Phase 4
22 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
23 Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing) Unknown status NCT00180206 Phase 4
24 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
25 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
26 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
27 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
28 A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis Unknown status NCT00808496 Phase 4
29 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
30 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
31 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
32 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
33 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
34 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
35 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
36 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
37 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
38 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
39 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Unknown status NCT02437461 Phase 4 Triamcinolone hexacetonide
40 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
41 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
42 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
43 Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study Unknown status NCT01623687 Phase 4
44 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cysts Unknown status NCT02154789 Phase 4 polidocanol
45 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
46 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
47 Corticosteroids as Additive in Arthrocentesis of the Temporomandibular Joint: Double Blind, Randomised Controlled Trial of Effectiveness. Unknown status NCT01275014 Phase 4 Dexamethasone;Isotonic saline
48 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
49 The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis. Unknown status NCT00513422 Phase 4
50 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%

Search NIH Clinical Center for Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Devil's claw preparation
Meclofenamate
Meclofenamate Sodium
Salsalate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Arthritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Arthritis:
AlloStem, adipose-derived mesenchymal stem cells combined with allograft bone for bone grafting
Embryonic/Adult Cultured Cells Related to Arthritis:
Adipose-derived mesenchymal stem cells combined with allograft bone (AlloStem) PMIDs: 22500696

Cochrane evidence based reviews: arthritis

Sources

Genetic Tests for Arthritis

About this section

Genetic tests related to Arthritis:

# Genetic test Affiliating Genes
1 Arthritis 29
Sources

Anatomical Context for Arthritis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Arthritis:

19
Joint, Skin Over The Joint

MalaCards organs/tissues related to Arthritis:

40
Bone, T Cells, Testes, Lung, Skin, B Cells, Heart
Sources

Publications for Arthritis

About this section

Articles related to Arthritis:

(show top 50) (show all 32044)
# Title Authors PMID Year
1
Anti-tumor necrosis factor treatment increases both the Th17 and Th22 T helper subsets in spondyloarthritis. 42
31512766 2019
2
The LMP2 CfoI polymorphism is associated with ankylosing spondylitis (AS) risk but not with acute anterior uveitis (AAU): A meta-analysis. 42
31702633 2019
3
Qmiiz ODT--an orally disintegrating meloxicam tablet. 42
31599868 2019
4
Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. 54 61
20447852 2010
5
Th17 cytokines and arthritis. 54 61
20127485 2010
6
Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. 54 61
19533138 2010
7
Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. 54 61
19949094 2010
8
Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists. 54 61
19804846 2010
9
PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. 54 61
19734303 2009
10
Self heat-shock protein 65-mediated regulation of autoimmune arthritis. 54 61
19800761 2009
11
Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. 54 61
19877043 2009
12
IL-17 as a future therapeutic target for rheumatoid arthritis. 54 61
19798029 2009
13
Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. 54 61
19732956 2009
14
Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. 54 61
19822058 2009
15
Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. 54 61
19052752 2009
16
Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. 54 61
19363453 2009
17
Tibetan Medicated-Bath Therapy may Improve Adjuvant Arthritis in Rat. 54 61
18955278 2009
18
Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. 54 61
19395871 2009
19
Anticytokine therapy in non-rheumatoid arthritis indications in 2009. 54 61
19342955 2009
20
Effect of pine pollen extract on experimental chronic arthritis. 54 61
19148883 2009
21
Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. 54 61
19652761 2009
22
Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? 54 61
19327240 2009
23
Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis? 54 61
19903325 2009
24
Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis. 54 61
19660107 2009
25
MEFV mutations in systemic onset juvenile idiopathic arthritis. 54 61
18984609 2009
26
The 'RASor's' edge: Ras proteins and matrix destruction in arthritis. 54 61
20067598 2009
27
Lessons from animal models of arthritis over the past decade. 54 61
19849822 2009
28
Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. 54 61
18674945 2008
29
Is tocilizumab an option for the treatment of arthritis? 54 61
18627338 2008
30
IL-33 exacerbates antigen-induced arthritis by activating mast cells. 54 61
18667700 2008
31
Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. 54 61
18576390 2008
32
Cartilage oligomeric matrix protein induction of chronic arthritis in mice. 54 61
18576344 2008
33
Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. 54 61
18612926 2008
34
Amelioration of collagen-induced arthritis by human recombinant soluble FcgammaRIIb. 54 61
18346938 2008
35
Interleukin-17 gene expression in patients with rheumatoid arthritis. 54 61
18092129 2008
36
EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease. 54 61
17988922 2007
37
[Paradoxical role of interferon-gamma in arthritis]. 54 61
17924123 2007
38
Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice. 54 61
17911637 2007
39
Rheumatoid arthritis and interleukin-32. 54 61
17619821 2007
40
[Rheumatoid arthritis and interleukin-32]. 54 61
17984580 2007
41
Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. 54 61
17597334 2007
42
The therapeutic potential of proteinase-activated receptors in arthritis. 54 61
17369094 2007
43
The immunology of rheumatoid arthritis. 54 61
17893995 2007
44
Effects of pravastatin in murine collagen-induced arthritis. 54 61
17119970 2007
45
Update on cytokines in rheumatoid arthritis. 54 61
17414959 2007
46
Use of infliximab to treat psoriatic arthritis in HIV-positive patients. 54 61
17321777 2007
47
TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. 54 61
17368068 2007
48
Collagen-induced arthritis in mice. 54 61
17983149 2007
49
A study of the arthritis pattern in primary Sjögren's syndrome. 54 61
17417996 2007
50
Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. 54 61
17127088 2006